Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer

IntroductionMetastatic breast cancer (MBC) is a diverse disease. Therapeutic options include hormonal therapy, chemotherapy, and targeted therapies. The optimal treatment sequence for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancer remains unknown.Method...

Full description

Bibliographic Details
Main Authors: Layal Al Mahmasani, Ghid Amhaz, Reine Abou Zeidane, Nathalie Chamseddine, Taha Hatab, Saad Sabbagh, Maya Charafeddine, Hazem I. Assi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
metastatic breast cancer
hormone therapy
chemotherapy
targeted therapies
sequence
preferences
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1181375/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1181375/full

Similar Items